Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
February 18, 2022
Pfizer and BioNTech have begun a trial of an Omicron-based COVID-19 vaccine. While research and real-world data show that boosters of the current vaccine available provide good protection against severe disease and hospitalization with the Omicron variant, the company is preparing in case the protection wanes over time and to address new variants that could arise.
The company plans to produce 4 billion COVID-19 vaccines in 2022, a number that is not expected to change if an adapted vaccine is required.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.